CivaTech Oncology, Inc., Corporation, a North Carolina-based company focused on localized radiation therapy, submitted a Form D for a $2.72M debt financing. The date of first sale was December 9, 2015, where […]
OncoTAb awarded National Cancer Institute contract for breast cancer therapy
OncoTAb, Inc. announced that the company was named as a recipient of a $300,000 grant by the National Cancer Institute (NCI) to begin pre-clinical development of a targeted therapy for triple negative breast […]
Anavex Signs Material Transfer Agreement with Biogen
Anavex Life Sciences Corp. announced the signing of a material transfer agreement with Biogen, wherein Biogen will test Anavex’s lead drug candidate, ANAVEX 2-73 in an oligodendrocyte precursor cell, OPC, differentiation assay. A satisfactory result […]
Tactical Therapeutics Presents Trial Results for Glioblastoma Treatment
Tactical Therapeutics, Inc., an emerging growth oncology drug development company, presented results of two Phase IB trials of its lead drug Carboxyamidotriazole Orotate (CTO, PRAVITNIB) at the American Society of Clinical Oncology […]
Lattice Biologics Doubles Current Private Placement to $1.5M
Lattice Biologics (TSX-V: LBL) (OTCBB: BLVKF) announced an increase in the size of its non-brokered private placement, from $750,000 to $1.5M in response to high investor demand. As a result, the funding […]
Zacks: Peregrine Pharma – On the Verge of Releasing First Oncology Drug to Market
Peregrine Pharma (PPHM) recently announced that the US. Food and Drug Administration (FDA) has approved on the design for their Phase III registration trial for its oncology drug, Bavituximab.
Motley Fool: Oncolytics – Cancer Killing Virus enters Phase II Metastatic Melanoma Trial
A unique drug is on the right pathway to success, as Oncolytics Biotechnology (ONCY) is pushing Reolysin through the pipeline. David Williamson from Motley Fool reported that this cancer medication is based off a common virus, incidentally referred to as the new “Cancer-Killing Virus.”
Biocentury: AVEO’s FDA Woes for Renal Cell Carcinoma Drug stops Astella’s Funding
AVEO Pharmaceuticals’ (AVEO) New Drug Application (NDA) with the FDA for their newly developed once a day oral medication to fight advanced renal cell carcinoma – known as Tivozanib – has hit a snag.Upon review, the FDA’s Oncologic Drugs Advisory Committee voted 13-1 against approval due to safety concerns.
